|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Aliskiren#Drug Interactions]] |
| {{Aliskiren}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| '''Cyclosporine''':Avoid co-administration of [[cyclosporine]] with aliskiren.
| |
| | |
| '''Itraconazole''': Avoid co-administration of [[itraconazole]] with aliskiren [See Clinical Pharmacology (12.3)].
| |
| | |
| '''Non-Steroidal Anti-Inflammatory Agents (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors)''': In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of [[NSAIDs]], including selective COX-2 inhibitors with agents that affect the renin-angiotensin-aldosterone system, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving aliskiren and NSAID therapy.
| |
| | |
| The antihypertensive effect of aliskiren may be attenuated by NSAIDs.
| |
| | |
| '''Dual Blockade of the renin-angiotensin-aldosterone system''': The concomitant use of aliskiren with other agents acting on the renin-angiotensin-aldosterone system such as ACEIs or ARBs is associated with an increased risk of [[hypotension]], [[hyperkalemia]], and changes in renal function (including acute renal failure) compared to monotherapy. Monitor blood pressure, renal function, and electrolytes in patients on aliskiren and other agents that affect the renin-angiotensin-aldosterone system [see Warnings and Precautions (5.4, 5.5, 5.9)].
| |
| | |
| The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated and should be avoided in patients with moderate renal impairment [see Contraindications (4) and Warnings and Precautions (5.2)].
| |
| | |
| '''Furosemide''': Oral co-administration of aliskiren and furosemide reduced exposure to furosemide. Monitor diuretic effects when furosemide is co-administered with aliskiren.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TEKTURNA (ALISKIREN HEMIFUMARATE) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=833c7a0b-5f64-4363-94d5-9a179049113a | publisher = | date = | accessdate = 25 February 2014 }}</ref>
| |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Agents acting on the renin-angiotensin system}}
| |
| | |
| [[Category:Renin inhibitors]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |